PharmiWeb Recruiter Blog

• ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex’s fully differentiated, insulin-producing, stem cell derived islets
• ViaCyte to be acquired for $320 million in cash

BOSTON--(BUSINESS WIRE)--Jul. 11, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.

Reboarding is the process of reintroducing employees to the workplace after they have been away for an extended period of leave, or after an organisation has experienced significant change. The goal of reboarding is to reassimilate employees back into their roles and the company culture of the organisation, whilst providing updates on new business goals, policies, and procedures.

France and Germany, July 6, 2022 – Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).

London, 05 July 2022 — Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+.

TNB-486 will be evaluated in multiple types of lymphoma

AstraZeneca today announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)ⁱ, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma¹.

• Medicines, including insulin, to be available in 40 lower-income countries
• Investment fund established to help create sustainable health systems
• Announcements comes as Global Health stakeholders gather in Paris

Paris – July 4, 2022 – Sanofi Global Health announces the launch of Impact^®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries.

• Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses
• Moderna would expand its presence in the UK through investments in R&D activities and capabilities
• Collaboration would support the UK with direct access to rapid pandemic response capabilities

CAMBRIDGE, MA / ACCESSWIRE / June 21, 2022 / Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the United Kingdom government to establish an mRNA Innovation and Technology Center in the UK. This state-of-the-art mRNA vaccine manufacturing facility is expected to provide access to rapid pandemic response capabilities and Moderna's respiratory virus vaccine candidates. Additionally, Moderna plans to expand its presence in the UK through investments in research and development (R&D) activities.

San Sebastián, Spain, June 21, 2022 - VIVEbiotech, S.L., a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited new facility is now fully operational after receiving the renewal of its GMP accreditation for a further three years.

The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) today announce a collaboration to accelerate the clinical development of adeno-associated virus (AAV) based gene therapies for dementia.

Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S. to increase diversity in clinical trials